title: [Consensus document for the treatment of bacteremia and endocarditis caused by methicillin-resistent Staphylococcus aureus. Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica].
abstract: Bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus (MRSA) are prevalent and clinically important. The rise in MRSA bacteremia and endocarditis is related with the increasing use of venous catheters and other vascular procedures. Glycopeptides have been the reference drugs for treating these infections. Unfortunately their activity is not completely satisfactory, particularly against MRSA strains with MICs > 1 microg/mL. The development of new antibiotics, such as linezolid and daptomycin, and the promise of future compounds (dalvabancin, ceftobiprole and telavancin) may change the expectatives in this field.The principal aim of this consensus document was to formulate several recommendations to improve the outcome of MRSA bacteremia and endocarditis, based on the latest reported scientific evidence. This document specifically analyzes the approach for three clinical situations: venous catheter-related bacteremia, persistent bacteremia, and infective endocarditis due to MRSA.
authors.affiliation: Servicio de Enfermedades Infecciosas, IDIBELL, Hospital Universitario de Bellvitge, Barcelona, España.
authors.forename: Francisco
authors.initials: F
authors.lastname: Gudiol
authors.forename: José María
authors.initials: JM
authors.lastname: Aguado
authors.forename: Alvaro
authors.initials: A
authors.lastname: Pascual
authors.forename: Miquel
authors.initials: M
authors.lastname: Pujol
authors.forename: Benito
authors.initials: B
authors.lastname: Almirante
authors.forename: José María
authors.initials: JM
authors.lastname: Miró
authors.forename: Emilia
authors.initials: E
authors.lastname: Cercenado
authors.forename: María de Los Angeles
authors.initials: Mde L
authors.lastname: Domínguez
authors.forename: Alex
authors.initials: A
authors.lastname: Soriano
authors.forename: Jesús
authors.initials: J
authors.lastname: Rodríguez-Baño
authors.forename: Jordi
authors.initials: J
authors.lastname: Vallés
authors.forename: Mercedes
authors.initials: M
authors.lastname: Palomar
authors.forename: Pilar
authors.initials: P
authors.lastname: Tornos
authors.forename: Emilio
authors.initials: E
authors.lastname: Bouza
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D016470:Bacteremia / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology; D002404:Catheterization / Q000009:adverse effects; D002405:Catheterization, Central Venous / Q000009:adverse effects; D002986:Clinical Trials as Topic; D020878:Device Removal; D024901:Drug Resistance, Multiple, Bacterial; D042241:Early Diagnosis; D004697:Endocarditis, Bacterial / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology / Q000601:surgery; D004866:Equipment Contamination; D019317:Evidence-Based Medicine; D006350:Heart Valve Prosthesis / Q000009:adverse effects; D019918:Heart Valve Prosthesis Implantation; D006801:Humans; D016106:Methicillin Resistance; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects / Q000302:isolation & purification*; D008826:Microbial Sensitivity Tests; D015995:Prevalence; D011446:Prospective Studies; D016459:Prosthesis-Related Infections; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology / Q000601:surgery; D014640:Vancomycin / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D014640:Vancomycin